The EPS projection of Core Laboratories N.V. (NYSE:CLB) for quarter ended 2016-09-30 is $0.37. A week before, the EPS forecast was $0.37 against target of $0.37, a month earlier. This estimate stood at $0.37 60 days earlier versus forecast of $0.37 90 days earlier, confirming a deviation of 0%.
Core Laboratories N.V. (NYSE:CLB) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 2.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 1, 0 and 1, respectively.
The downgrade of EPS estimates for Core Laboratories N.V. (NYSE:CLB) in the preceding 120, 60, 30 and 90 days were 3, 2, 1 and 2, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Core Laboratories N.V. (NYSE:CLB) was $0.37. This projection was computed after accounting 5 calls. As reported on 2016-04-20 the EPS was $0.37. The change was $0, demonstrating a percentage deviation of 0%. The projections confirmed a standard deviation of 0.02.
Quarterly Sales Estimates
For the fiscal 2017, the yearly sales target for Core Laboratories N.V. (NYSE:CLB) stands at $160.1 and the median estimate at $160.1. Almost 2 analysts announced their estimates.
The highest estimate is $161.6 while the lowest target is $158.6 showing standard deviation of 2.121%.
As many as 2 analysts released sales estimates reised in upside while 2 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 2 revised sales number projection on upside while 2 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 2 hiked sales estimations and 2 reduced sales forecast. Core Laboratories N.V. (NYSE:CLB) stated that the change in forecast was -5.489%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...